Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (95)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (4)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Myeloma (293)
  5. Survivorship Research (212)
  6. Hematologic Malignancies Research (209)

More Groups

People
  1. Neha Korde (188)
  2. Alexander Lesokhin (167)
  3. Hani Hassoun (160)
  4. Sergio Giralt (158)
  5. Malin Hultcrantz (155)
  6. Heather Landau (144)

More People

Years
  1. 2025 (9)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (95)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. JAMA Oncology (12)
  5. Blood Cancer Journal (11)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (105)
  2. Elsevier Inc. (70)
  3. Nature Publishing Group (25)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets
    Meeting Abstract

    Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: A phase 2 nonrandomized controlled trial
    Journal Article

    Kazandjian, D.; Hill, E.; Dew, A.; Morrison, C.; Roswarski, J.; Korde, N.; Emanuel, M.; Petrosyan, A.; Bhutani, M.; Calvo, K. R.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies
    Journal Article

    Chung, D. J.; Shah, G. L.; Devlin, S. M.; Ramanathan, L. V.; Doddi, S.; Pessin, M. S.; Hoover, E.; Marcello, L. T.; Young, J. C.; Boutemine, S. R.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing
    Journal Article

    Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Du, F.; Qu, J.; Chaudhari, J.; Thummar, K.; Zhu, M.; Shen, L. B.; Hall, M.; more...
    Molecular Therapy - Methods & Clinical Development (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Cellular therapy during COVID-19: Lessons learned and preparing for subsequent waves
    Journal Article

    Nawas, M. T.; Shah, G. L.; Feldman, D. R.; Ruiz, J. D.; Robilotti, E. V.; Aslam, A. A.; Dundas, M.; Kamboj, M.; Barker, J. N.; Cho, C.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Assessment of outcomes associated with the use of newly approved oncology drugs in medicare beneficiaries
    Journal Article

    Green, A. K.; Curry, M.; Trivedi, N.; Bach, P. B.; Mailankody, S.
    JAMA Network Open (2021)

    Fulltext@MSK | Save
  • Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Journal Article

    Eveillard, M.; Korde, N.; Ciardiello, A.; Diamond, B.; Lesokhin, A.; Mailankody, S.; Smith, E.; Hassoun, H.; Hultcrantz, M.; Shah, U.; more...
    Clinica Chimica Acta (2021)

    Fulltext@MSK | Save